Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer
Authors:
- Marcus VetterMarcus Vetter
- Julia LandinJulia Landin
- Barbara Maria SzczerbaBarbara Maria Szczerba
- Francesc Castro-GinerFrancesc Castro-Giner
- Sofia GkountelaSofia Gkountela
- Cinzia DonatoCinzia Donato
- Ilona KrolIlona Krol
- Ramona ScherrerRamona Scherrer
- Catharina BalmelliCatharina Balmelli
- Alexandra MalinovskaAlexandra Malinovska
- Alfred ZippeliusAlfred Zippelius
- Christian KurzederChristian Kurzeder
Open Access
- 20 November 2018
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 20 (1) , 141
Abstract
The presence of circulating tumor cells (CTCs) in patients with breast cancer correlates to a bad prognosis. Yet, CTCs are detectable in only a minority of patients with progressive breast cancer, and factors that influence the abundance of CTCs remain elusive. We conducted CTC isolation and enumeration in a selected group of 73 consecutive patients characterized by progressive invasive breast cancer, high tumor load and treatment discontinuation at the time of CTC isolation. CTCs were quantified with the Parsortix microfluidic device. Clinicopathological variables, blood counts at the time of CTC isolation and detailed treatment history prior to blood sampling were evaluated for each patient. Among 73 patients, we detected at least one CTC per 7.5 ml of blood in 34 (46%). Of these, 22 (65%) had single CTCs only, whereas 12 (35%) featured both single CTCs and CTC clusters. Treatment with the monoclonal antibody denosumab correlated with the absence of CTCs, both when considering all patients and when considering only those with bone metastasis. We also found that low red blood cell count was associated with the presence of CTCs, whereas high CA 15-3 tumor marker, high mean corpuscular volume, high white blood cell count and high mean platelet volume associated specifically with CTC clusters. In addition to blood count correlatives to single and clustered CTCs, we found that denosumab treatment associates with most patients lacking CTCs from their peripheral circulation. Prospective studies will be needed to validate the involvement of denosumab in the prevention of CTC generation.Keywords
Funding Information
- European Research Council
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Krebsliga Schweiz
- Krebsliga Beider Basel
- Eidgenössische Technische Hochschule Zürich
- Universität Basel
This publication has 24 references indexed in Scilit:
- RANK expression as a prognostic and predictive marker in breast cancerBreast Cancer Research and Treatment, 2014
- RANK expression on breast cancer cells promotes skeletal metastasisClinical & Experimental Metastasis, 2013
- Denosumab: mechanism of action and clinical outcomesInternational Journal Of Clinical Practice, 2012
- Bisphosphonates for Osteoporosis — Where Do We Go from Here?New England Journal of Medicine, 2012
- HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysisBreast Cancer Research and Treatment, 2011
- Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentBreast Cancer Research, 2011
- The distinctive biology of cancer in adolescents and young adultsNature Reviews Cancer, 2008
- Comparison of Age Distribution Patterns for Different Histopathologic Types of Breast CarcinomaCancer Epidemiology, Biomarkers & Prevention, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- The Relation between Survival and Age at Diagnosis in Breast CancerNew England Journal of Medicine, 1986